The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Sutro Biopharma, a Phase 1 biotech developing next-generation immuno-oncology therapies, raised $85 million by offering 5.67 million shares at $15, the midpoint of the $14 to $16 range. The company raised $10 million more than it had planned (+13%) by...read more
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Sutro Biopharma, a Phase 1 biotech developing next-generation immuno-oncology therapies, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to...read more
US IPO Weekly Recap: 12 IPOs wrap up active third quarter as SurveyMonkey pops 34%
The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Sutro Biopharma prices upsized IPO at $15 midpoint
Sutro Biopharma, a Phase 1 biotech developing next-generation immuno-oncology therapies, raised $85 million by offering 5.67 million shares at $15, the midpoint of the $14 to $16 range. The company raised $10 million more than it had planned (+13%) by...read more
US IPO Week Ahead: 13 IPOs close out 3rd quarter with biotechs, China and SurveyMonkey
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Immuno-oncology biotech Sutro Biopharma sets terms for $75 million IPO
Sutro Biopharma, a Phase 1 biotech developing next-generation immuno-oncology therapies, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to...read more